Worlds Smallest LED is a Single Molecule By coaxing light out of…


By coaxing light out of a single polymer molecule, researchers have made the world’s tiniest light-emitting diode.

 

Worlds Smallest LED is a Single Molecule
By coaxing light out of a single polymer molecule, researchers have made the world’s tiniest light-emitting diode.
This work is part of an interdisciplinary effort to make molecular scale electronic devices, which hold the potential for creating smaller but more powerful and energy-efficient computers. Guillaume Schull and his colleagues at the University of Strasbourg in France made the device with the conducting polymer polythiophene. They used a scanning tunneling microscope tip to locate and grab a single polythiophene molecule lying on a gold substrate. Then they pulled up the tip to suspend the molecule like a wire between the tip and the substrate.
The researchers report in the journalPhysical Review Letters that when they applied a voltage across the molecule, they were able to measure a nanoampere-scale current passing through it and to record light emitted from it.
(via First Single-Molecule LED - IEEE Spectrum)

This work is part of an interdisciplinary effort to make molecular scale electronic devices, which hold the potential for creating smaller but more powerful and energy-efficient computers. Guillaume Schull and his colleagues at the University of Strasbourg in France made the device with the conducting polymer polythiophene. They used a scanning tunneling microscope tip to locate and grab a single polythiophene molecule lying on a gold substrate. Then they pulled up the tip to suspend the molecule like a wire between the tip and the substrate.

The researchers report in the journalPhysical Review Letters that when they applied a voltage across the molecule, they were able to measure a nanoampere-scale current passing through it and to record light emitted from it.

‘Brain hub predicts negative events’


Scientists say a part of the brain, smaller than a pea, triggers the instinctive feeling that something bad is about to happen.

Writing in the journal PNAS, they suggest the habenula plays a key role in how humans predict, learn from and respond to nasty experiences.

And they question whether hyperactivity in this area is responsible for the pessimism seen in depression.

They are now investigating whether the structure is involved in the condition.

Picture of a person in an alleyway

“Start Quote

“Everything that moves needs a system like this – to tell us not to stroke the tiger or go down a dark alley”

Dr Jonathan RosierUniversity College London

Money or shock

Animal studies have shown that the habenula fires up when subjects expect or experience adverse events, But in humans this tiny structure (less than 3mm in diameter) has proved difficult to see on scans.

Inventing a technique to pinpoint the area, scientists at University College London put 23 people though MRI scanners to monitor their brain activity.

Participants were shown a range of abstract pictures. A few seconds later, the images were linked to either punishment (painful electric shocks), reward (money) or neutral responses.

For some images, a punishment or reward followed each time but for others this varied – leaving people uncertain whether they were going to feel pain or not.

And when people saw pictures associated with shocks the habenula lit up.

And the more certain they were a picture was going to result in a punishment, the stronger and faster the activity in this area.

Scientists suggests the habenula is involved in helping people learn when it is best to stay away from something and may also signal just how bad a nasty event is likely to be.

Depressive symptoms

Dr Jonathan Roiser, a lead author on the paper from University College London, told the BBC:

“Everything that moves needs a system like this – to tell us not to stroke the tiger or go down a dark alley.

“It is likely the habenula is a key neural hub allowing us to anticipate such events.”

This area of the brain has been seen to be overactive in animal experiments on depression.

And in one human case-study, providing deep brain stimulation (electrical current) to this area helped reduce depressive symptoms.

Prof Catherine Harmer, at the University of Oxford, who was not involved in the research, said: “This is an important piece of work and has the potential to have great significance in depression.

“If this area is involved in this illness, it may help explain why people suffering from major depression show an over-sensitivity to punishments and are less likely to respond to rewards.”

Scientists are now working with people with depression to investigate any differences in brain activity in this area.

How faces drive first impressions


Whether it’s a curled lip or a keen cheekbone, we all make quick social judgements based on strangers’ faces.

Now scientists have modelled the specific physical attributes that underpin our first impressions.

elderly face

Small changes in the dimensions of a face can make it appear more trustworthy, dominant or attractive.

The results, published in the journal PNAS, could help film animators or anyone looking to create an instant impression on a social network.

Dr Tom Hartley, a neuroscientist at the University of York and the study’s senior author, said the work added mathematical detail to a well-known phenomenon.

“If people are forming these first impressions, just based on looking at somebody’s face, what is it about the image of the face that’s giving that impression – can we measure it exactly?”

Three key dimensions of a first impression

  • Approachability: how likely is this person to help (or hinder) me?
  • Dominance: how capable is this person of carrying out those intentions?
  • Attractiveness: is this person young and good looking – a potential romantic partner?

Positive first impressions are especially important in a world dominated by social media, from LinkedIn to Tinder.

Dr Hartley sees the commercial potential in applying his numerical model to the photos people use to present themselves online. “It’s obviously potentially very useful,” he told the BBC.

To make the calculations, each of 1,000 face photos from the internet was shown to at least six different people, who gave it a score for 16 different social traits, like trustworthiness or intelligence.

Overall, these scores boil down to three main characteristics: whether a face is (a) approachable, (b) dominant, and (c) attractive.

By measuring the physical attributes of all 1,000 faces and putting them together with those scores, Dr Hartley and his team built a mathematical model of how the dimensions of a face produce those three impressions.

The next step was to get the computer to extrapolate. Using their new model, the team produced cartoon versions of the most (and least) approachable, dominant and attractive faces – as well as all the possibilities in between.

Tramadol – Top 8 Things You Need to Know


Tramadol (Ultram, Ultram ER, ConZip, Ryzolt and Rybix ODT) is a centrally-acting, oral narcotic analgesic and is approved for the treatment of moderate to moderately severe pain in adults. The extended-release form of tramadol is for around-the-clock treatment of pain and not for use on an as-needed basis for pain. A combination product of tramadol and acetaminophen (Ultracet) is also available by prescription. In 2013, over 43 million tramadol prescriptions were written in the U.S, according to IMS.

In 1995, tramadol was originally approved by the U.S. Food and Drug Administration (FDA) as a non-controlled analgesic. However, since 1995, changes to the controlled substance status of tramadol have been made due to reports of drug abuse and diversion. The Drug Abuse Warning Network (DAWN) reported that roughly 20,000 emergency department visits were related to tramadol non-medical use in 2011. According to the National Survey on Drug Use and Health (NSDUH) in 2012, 3.2 million people in the U.S. aged 12 or older used tramadol for nonmedical purposes.

1. Tramadol is now a controlled substance in all 50 U.S. states.

On July 7, 2014 the U.S. Drug Enforcement Administration (DEA) announced that tramadol has been placed into schedule IV of theControlled Substances Act (CSA) effective August 18, 2014. The new scheduling applies to all forms of tramadol. The rescheduling of tramadol comes at a time of growing concern related to abuse, misuse, addiction and overdose of opioid analgesics. Previously tramadol was a controlled substance in only a few states.

Starting August 18, 2014 tramadol prescriptions may only be refilled up to five times within a six month period after the date on which the prescription was written. After five refills or after six months, whichever occurs first, a new prescription is required. This rule applies to all controlled substances in schedule III and IV.

2. Tramadol is associated with a wide array of side effects.

In many people, tramadol is well-tolerated when used for pain, but tramadol can also cause some common and serious side effects. It is important to review with your doctor the side effects that have been reported with tramadol before starting treatment. Side effects with tramadol may worsen with higher doses.

Common side effects may include:

  • itching
  • headache
  • diarrhea
  • nausea
  • vomiting
  • constipation
  • dizziness
  • drowsiness
  • impaired mental abilities

Serious (but less common or even rare) side effects may include:

  • seizures
  • serotonin syndrome
  • depressed breathing
  • life-threatening allergic reactions
  • angioedema, or swelling under the skin
  • possibly fatal skin reactions
  • orthostatic hypotension (low blood pressure that occurs when you stand up from sitting or lying down)
  • suicide thoughts or action
  • withdrawal symptoms

Seizures have occurred in patients taking recommended doses but are more likely at high doses associated with abuse of tramadol.

Do not abruptly stop taking tramadol as withdrawal symptoms like nausea, diarrhea, anxiety, or tremors may occur. Consult with your doctor for a tapering dose schedule if you are stopping tramadol treatment.

3. Dangerous drug interactions are possible with tramadol.

Tramadol may cause a dangerous condition known as “serotonin syndrome”. Patients receiving serotonergic drugs such as the migraine agents called “triptans” may be at a higher risk for serotonin syndrome. Brand names of triptans include ImitrexZomigFrovaMaxaltAxert,Amerge, and Relpax.

Do not take tramadol if you have used alcohol, sedatives, tranquilizers, or narcotic medications. Tramadol should not be combined with these medications or with alcohol at any time. Patients should avoid driving or other activities that require mental alertness until the effects of the drug are known.

Patients should always have a drug interaction review completed each time they start a new medication, including herbal, over-the-counter, and supplement drugs.

4. Tramadol can be habit-forming.

Tramadol is structurally related to the opioids like codeine and morphine and can lead to psychological and physical dependence, addiction, and withdrawal. People with a history of a drug-seeking behavior may be at greater risk of addiction, but illicit actions to obtain the drug can occur in people without a prior addiction, as well.

Do not abruptly stop taking tramadol as withdrawal symptoms like nausea, diarrhea, anxiety, sweating, difficulty in sleep, shivering, pain, tremors, or rarely, hallucinations may occur.

Consult with your doctor before discontinuing tramadol treatment; do NOT discontinue treatment on your own. Withdrawal symptoms may be relieved by re-initiation of opioid therapy followed by a slow, dose reduction combined with symptomatic support, as directed by your doctor.

5. Support groups exist within Drugs.com.

Support groups may be helpful for patients who take tramadol, who use medications for pain relief, who are in need of addiction support, and for many other needs. Joining one or more support groups is a great way to discover others with related medications and similar conditions, find out more information and share your own experience.

6. Tramadol is available in both immediate-release and extended-release formulations.

Both the immediate-release and extended-release formulation of tramadol are available generically and can possibly save you hundreds of dollars on your prescription.

If you prefer generic medications due to cost-savings, ask your physician to only write for generic drugs whenever possible. If you cannot afford your medication, do not walk away from the pharmacy. Ask your doctor or pharmacist for more affordable alternatives.

Tramadol extended-release tablets must be taken whole, not split, chewed or crushed.

Learn more about generic drugs in “Facts About Generic Drugs”.

7. Dose adjustments are needed in the elderly, and in those with kidney or liver problems.

 

As with many medications, if you are young, elderly, or have kidney or liver disease dose adjustments http://www.drugs.com/dosage/tramadol.html are often required. The dosing interval (how often you take the drug) may be adjusted, the actual dose of the drug may be reduced, and you may have a maximum dose you should not exceed per day. Talk to your doctor about the need for adjusted doses with any medication.

Patients older than 65 years of age

Doses should usually start at the low end of the dosing range and can be titrated upwards slowly based on tolerance and effectiveness.

Patients older than 75 years of age

Maximum dose of regular-release oral tablets: 300 mg per day in divided doses.

Kidney Disease

Over 30 percent of tramadol is excreted by the kidneys as the unchanged molecule, which could lead to toxic blood levels in patients with kidney disease.

Creatinine clearance is a lab test that measures how well your kidneys are working. If you use the immediate-release form of tramadol (not the ER form), and have a creatinine clearance of less than 30 (severe kidney disease), your dosing interval should be increased to every 12 hours, and the maximum daily dose of tramadol is 200 milligrams (mg).

Do not use the extended-release form of tramadol if your creatinine clearance is less than 30 (severe kidney disease).

Liver Disease

In patients with cirrhosis, the regular-release tablets and oral disintegrating tablets can be given at a dose of 50-mg orally every 12 hours, with a maximum dose of 100-mg per day.

Extended-release tablets and the brand name form of tramadol called Ryzolt should not be used in patients with severe hepatic impairment (Child-Pugh Class C).

8. There are ways to engage with other patients using tramadol.

There are over 700 reviews for tramadol from patients who use this drug for pain, back pain and other various conditions (some of which may be off-label use, meaning the drug is not approved by the FDA for that particular use). Here you can ask a question, share an experience and see other ratings from patients who are using tramadol for various conditions.

Remember, the information is NOT intended to endorse tramadol or recommend therapy. While these reviews might be helpful to you, they are NOT a substitute for the expertise, skill, knowledge and judgement of healthcare practitioners in patient care.

 

FDA Expands Approved Use of Imbruvica for Chronic Lymphocytic Leukemia


The U.S. Food and Drug Administration today expanded the approved use ofImbruvica (ibrutinib) to treat patients with chronic lymphocytic leukemia (CLL) who carry a deletion in chromosome 17 (17p deletion), which is associated with poor responses to standard treatment for CLL. Imbruvica received a breakthrough therapy designation for this use.

The FDA is also approving new labeling to reflect that Imbruvica’s clinical benefit in treating CLL has been verified. In February 2014, Imbruvica received accelerated approval to treat CLL based on its effect on overall response rate. New clinical trial results examining progression-free survival and overall survival have confirmed the drug’s clinical benefit.

A type of non-Hodgkin lymphoma, CLL is a rare blood and bone marrow disease that usually gets worse slowly over time, causing a gradual increase in white blood cells called B lymphocytes, or B cells. The National Cancer Institute estimates that 15,720 Americans will be diagnosed and 4,600 will die from CLL in 2014. Imbruvica works by blocking the enzyme that allows cancer cells to grow and divide.

“We continue to see advances in the availability of therapies to treat chronic lymphocytic leukemia, especially for difficult-to-treat patient populations,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “Imbruvica is the fourth drug approved to treat CLL that received a breakthrough therapy designation, reflecting the promise of the breakthrough therapy designation program and demonstrating the FDA’s commitment to working cooperatively with companies to expedite the development, review and approval of these important new drugs.”

The other three drugs approved to treat CLL that received breakthrough designations are Gazyva (obinutuzumab) in November 2013, Arzerra (ofatumumab) in April 2014 and Zydelig (idelalisib) in July 2014. Imbruvica’s application for accelerated approval to treat CLL did not receive breakthrough therapy designation.

Today’s approval actions for Imbruvica are based on a clinical study of 391 previously treated participants, 127 of whom had CLL with 17p deletion. Participants were randomly assigned to receive Imbruvica or Arzerra until disease progression or side effects became intolerable.

The trial was stopped early for efficacy after a pre-planned interim analysis showed Imbruvica-treated participants experienced a 78 percent reduction in risk of disease progression or death (progression-free survival). Results also showed a 57 percent reduction in risk of death (overall survival) in participants treated with Imbruvica. Of the 127 participants who had CLL with 17p deletion, those treated with Imbruvica experienced a 75 percent reduction in risk of disease progression or death.

The most common side effects associated with Imbruvica observed in the clinical study include low levels of platelets in the blood (thrombocytopenia), a decrease in infection-fighting white blood cells called neutrophils (neutropenia), diarrhea, low red blood cells (anemia), fatigue, pain in the muscles and bones (musculoskeletal pain), upper respiratory tract infection, rash, nausea and fever (pyrexia).

Imbruvica’s new use is being approved more than two months ahead of the product’s prescription drug user fee goal date of Oct. 7, 2014, the date the FDA was scheduled to complete review of the drug application. The FDA reviewed Imbruvica’s application for this new use under the agency’s priority review program, which provides for an expedited review of drugs that are intended to treat a serious disease or condition and, if approved, would offer significant improvement compared to marketed products.

Imbruvica also received accelerated approval in November 2013 for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. Clinical studies to verify and describe Imbruvica’s clinical benefit in mantle cell lymphoma are ongoing.

Imbruvica is co-marketed by Pharmacyclics, based in Sunnyvale, Calif., and Janssen Biotech, based in Horsham, Penn.

Source: FDA

 

Potential ‘universal’ blood test for cancer discovered — ScienceDaily


http://www.sciencedaily.com/releases/2014/07/140728094410.htm?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+sciencedaily%2Ftop_news%2Ftop_science+%28ScienceDaily%3A+Top+Science+News%29&utm_content=FaceBook

From the desk of Zedie.

Vancomycin-Resistant Staphylococcus aureus .


 

After emerging in the 1990s, community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) spread rapidly across the U.S. Fortunately, most infections caused by these organisms have been skin abscesses with low risk for serious complications. In 2002, the vanA gene cluster, which confers vancomycin resistance, was described in MRSA. Despite fears that vancomycin-resistant MRSA (VRSA) strains would become common, only 13 VRSA isolates have been reported in the U.S. — all from patients with skin or soft-tissue infections. Multilocus sequence typing has shown that 12 of them belong to clonal complex 5, which is hospital-associated.

Now, investigators have described a patient in Brazil who underwent multiple courses of antibiotic therapy, including glycopeptides, for a serious skin condition. He developed a bloodstream infection caused by a CA-MRSA strain that was initially vancomycin susceptible but acquired the vanA gene cluster during antibiotic therapy

Several molecular and genetic techniques were used to characterize the patient’s isolates.

Based on multilocus sequence typing, the patient’s vancomycin-resistant strain was closely related to CA-MRSA USA300-ST8 strains that have SCCmec type IVa and are now found in several regions worldwide. The strain differed from the usual USA300 strains (including one reported from the northern part of South America) in that it lacked the genes encoding Panton–Valentine leukocidin. A conjugative plasmid, pBRZ01, carried the vanA cluster and could be readily transferred to other S. aureus strains.

Comment

Although just a case report, this paper deserves coverage because it demonstrates that a community-associated methicillin-resistant S. aureus strain that developed vancomycin resistance can cause serious invasive infection. Dissemination of this or other, similar strains could have major public health implications on a global scale.

 

Faster, Easier Cures for Hepatitis C


Transformative advances in drug treatments approved by the Food and Drug Administration are giving the 3.2 million Americans with chronic hepatitis C a chance for a longer, healthier life without the virus. That’s welcome news for baby boomers—who make up three of four adults with the hepatitis C virus—and millions of other Americans, many of whom don’t yet know they are infected and carriers.

Hepatitis C can be cured, and today’s drug therapies are very effective and easier for patients to take, says Jeffrey S. Murray, M.D., the deputy director of the Division of Antiviral Products in FDA’s Center for Drug Evaluation and Research. Murray is an internist who specializes in infectious diseases.

 

A Preventable and Curable Disease

Hepatitis (inflammation of the liver) refers to a group of viral infections that affect the liver. The most common types are hepatitis A, hepatitis B and hepatitis C. Each is caused by a different virus.

Hepatitis C is the most common chronic blood-borne infection in the United States. There is no vaccine for this disease, but hepatitis C can be prevented by avoiding behaviors that can spread the virus—including sharing needles, syringes or other equipment to inject drugs.

A diagnosis of hepatitis C no longer means months and months of painful drug injections, which for decades were the only option. Science is making strides in therapies, giving patients new alternatives.

“Interferon-based injections often make patients feel ill and give them flulike symptoms,” Murray says. The treatment by interferon also lasts six months to a year, and cures only 40% to 50% of hepatitis C patients.

“Patients with very advanced liver disease couldn’t take the traditional treatment because often those injections could make them worse,” he adds. “Now, patients can treat their hepatitis C with only pills– drug combinations that are faster and have a higher cure rate.”

Today’s pills have double the viral cure rates—90% to 100%—in just in 12 weeks’ time. Reducing the treatment from a year to three months is a huge advantage for people with hepatitis C, especially because it’s easier to swallow a pill than to get an injection, Murray says.

The new regimens include Sovaldi (sofosbuvir), which is the first drug approved to treat certain types of hepatitis C infection without the need to co-administer interferon. In recent years, FDA has also approved three protease inhibitors—Olysio (simeprevir), Victrelis (boceprevir) and Incivek (telaprevir)—to treat chronic hepatitis C virus infection. Olysio is a protease inhibitor that blocks a specific protein the hepatitis C virus needs to replicate. The drug is a component of a combination antiviral treatment regimen.

FDA provides information through a Hepatitis e-mails list, along with notices of upcoming public events, such as advisory committee meetings, and opportunities to comment on policies and issues that affect people with hepatitis B or C.

 

Baby Boomers and Hepatitis C

For most people, hepatitis is a silent disease until it causes substantial damage to the liver. That process may take several years, and can lead to liver failure, liver transplantation and liver cancer.

“Hepatitis C is a bit like smoking, the longer you’ve had it, the higher your risk of developing complications—in this case, liver cancer and end-stage liver disease. It’s a progressive disease that takes years, even decades, before the patient develops cirrhosis or cancer,” Murray says. “The good news is that when you cure hepatitis C, you also lower its risks, though you don’t completely erase the years of damage to your liver.”

Once infected with the hepatitis C virus, nearly 8 in 10 untreated people remain infected for life, according to the Centers for Disease Control and Prevention (CDC). Three in four patients with chronic hepatitis C are baby boomers (people born from 1945 to 1965), and many became infected before the virus was identified and the blood supply was tested for the disease. That’s why it’s important for baby boomers—there are 76.4 million of them, according to the U.S. Census Bureau—to take a simple blood test for hepatitis C.

“When it comes to hepatitis C, the outlook for the future is better, but the past is catching up with us—especially if you are a baby boomer,” Murray says. “Still, this is a fortuitous time because better hepatitis C treatments are becoming available just as the patient population at risk of long-term complications is about to peak. There are treatments for chronic hepatitis and many reasons to get tested now more than ever because of the availability of safe and effective therapies.”

Sperm Count Test: Guys Should Avoid These 6 Things That Are Destroying Their Sperm Count.


Men worry so much about the amount of sperm they produce that they sometimes forget how important the quality of their sperm is to fertility. Unfortunately, around 15 percent of couples are unable to conceive a child after a year or more of unprotected sex. Male infertility can be caused by several factors including the production, motility (the ability to move spontaneously and actively), and blockage of sperm. Excessive alcohol and tobacco use have been known to limit the production of sperm and damage its quality, but what are some other behavioral and environmental factors that can ruin a man’s chance of conceiving? Here are six things that men may not realize are destroying their sperm count:

Male Fertility

1. Eating Bacon

A crispy strip of bacon may be delicious, but research shows it could also be destroying your sperm count. A recent study conducted at Harvard University included 156 men enrolled in an in vitro fertilization (IVF) trial. Lead researcher Dr. Myriam Afeiche and colleagues from the university tracked the eating habits of each male participant and his female partner, including how often they ate processed meat, red meat, white meat, poultry, and fish. Men who ate half a portion or more of processed meat a day recorded 5.5 percent normal-shaped sperm compared to 7.2 percent in men who ate less than half a portion. On the other hand, men who reported eating a healthy portion of fish actually improved the quality of their sperm.

“We found the effect of processed meat intake lowered quality and fish raised quality,” Dr. Afeiche explained.

2. Sweating It Out in a Sauna

If you’re looking for a healthy way to sweat out all of your body’s toxins, you may want to avoid trips to the sauna. Researchers from the University of Padova in Italy asked 10 healthy Finnish men in their thirties to participate in 15-minute sauna sessions twice a week for three months. Each study participant reported normal sperm count prior to the sauna regimen and no history of sauna use in the past year. They were also asked to provide blood and semen samples and had their scrotal temperatures taken before and after each sauna session. The group’s sperm count and concentration experienced a significant drop off after three months of 15-minute sauna sessions and remained low in the three months following the program. However, sperm production was restored to normal levels after six months.

“Avoidance of testicular heating and in particular of sauna exposure (in those countries where sauna is largely used) could be suggested in the counseling of males seeking fertility [treatment],” lead researcher Carlo Foresta told LiveScience.

3. Stressing Out About Life

Stress and anxiety can have a damaging effect on our overall health, including male fertility. Take for example a recent study involving 193 men between the ages of 38 and 49 who were assessed by a subjective and objective scale including life events that led up to stress at work and in life. Semen samples provided by each male participant were analyzed by University of California-Davis technicians for sperm appearance, motility, and semen concentration. While men who reported stressful life events suffered from impaired fertility, stress at the workplace had no damaging effect on semen quality. Work stress, however, did lower the group’s testosterone levels.

“Men who feel stressed are more likely to have lower concentrations of sperm in their ejaculate, and the sperm they have are more likely to be misshapen or have impaired motility,” said Dr. Pam Factor-Litvak, senior author and associate professor of epidemiology at the Mailman School of Public Health, in a statement. “These deficits could be associated with fertility problems.”

4. Using Your Laptop

You may recall being told to keep your laptop off of your lap to prevent the heat from damaging your sperm count, but you may not know that even a computer’s Wi-Fi connection can hinder male fertility. A recent study published in the journal Fertility and Sterility collected 29 sperm samples from healthy men that were placed underneath laptop with a wireless Internet connection for four hours. Researchers set the laptop to download and upload information so its Wi-Fi was in constant use. To prove that temperature wasn’t the only factor effecting sperm quality, an air-conditioning system was used to keep the laptop at 77 degrees. Radiation from the laptop’s Wi-Fi connection caused DNA damage and less motility in sperm.

5. Being Exposed to Pesticides

Exposure to pesticides has been implicated in a variety of health complications, including birth defects, nerve damage, cancer, and even decreased sperm count.  A research team from George Washington University’s Department of Environmental and Occupational Health investigated 17 recent studies testing the effects of certain pesticides on male fertility. Researchers targeted studies that involved pyrethroids and organophosphates, two pesticides that humans are commonly exposed to. Out of all 17 studies, 15 reported significant damage to sperm quality due to pesticide exposure. Almost all studies found that sperm concentration had decreased while some reported sperm motility obstruction.

6. Smoking Marijuana

With all the research coming to light surrounding the alleged healthy effects of marijuana use, it may be hard for men to accept what cannabis is doing to their fertility. University of Buffalo researchers who tested the sperm quality and concentration of frequent marijuana smokers found that their little swimmers were burnt out before reaching the egg because they had swam too fast too early. To examine the effect marijuana’s main component, tetrahydrocannabinol (THC), had on sperm, the research team tested semen samples from 22 men who reported smoking marijuana at least 14 times a week for five years. Laboratory tests confirmed that when sperm was exposed to THC it began to swim erratically and was unable to start the fertilization process by attaching itself to an egg.

“The sperm from marijuana smokers were moving too fast too early,” said lead researcher Dr. Lani Burkman. “The timing was all wrong. These sperm will experience burnout before they reach the egg and would not be capable of fertilization.”

WiFi Radiation – Dangers of WiFi – See It Measured – How To Remediate WiFi Radiation.


This video provides a simple, yet profound lesson. The radio frequency (microwave) radiation being transmitted from your wireless router or modem is extremely toxic and detrimental to your health. Notice how high the measurements are on the RF meter! Most of us are living and working in this type of RF radiation exposure every single day and night. The fix, or remediation is simple. Plug your modem or router into your computer using an Ethernet cord (hardwire), and “disable” the wireless function on your modem or router. This is very important for the health and safety of all those in your home or office. If you need to use the wireless function, then turn it on for a short time, do your task or watch your movie, then disable it once again. Never leave your wireless internet on all night as it will cause sleep disturbances which lead to even worse health issues. The fix is simple! Use an Ethernet cord and disable the wireless function.

http://tv.naturalnews.com/v.asp?v=654BBDAC54B9DA8F49AB899E4CE60CB5&utm_content=bufferac324&utm_medium=social&utm_source=facebook.com&utm_campaign=buffer

From the desk of Zedie.